Literature DB >> 18615105

Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.

V G Oehler, J Qin, R Ramakrishnan, G Facer, S Ananthnarayan, C Cummings, M Deininger, N Shah, F McCormick, S Willis, A Daridon, M Unger, J P Radich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18615105      PMCID： PMC3655797          DOI： 10.1038/leu.2008.183

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Microfluidic digital PCR enables multigene analysis of individual environmental bacteria.

Authors:  Elizabeth A Ottesen; Jong Wook Hong; Stephen R Quake; Jared R Leadbetter
Journal:  Science       Date:  2006-12-01       Impact factor: 47.728

Review 2.  Evaluating markers for the early detection of cancer: overview of study designs and methods.

Authors:  Stuart G Baker; Barnett S Kramer; Martin McIntosh; Blossom H Patterson; Yu Shyr; Steven Skates
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

3.  Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).

Authors:  F E Nicolini; S Corm; Q-H Lê; N Sorel; S Hayette; D Bories; T Leguay; L Roy; S Giraudier; M Tulliez; T Facon; F-X Mahon; J-M Cayuela; P Rousselot; M Michallet; C Preudhomme; F Guilhot; C Roche-Lestienne
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

4.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Ian Parkinson; Andrew Grigg; Jeff Szer; Kerry Taylor; Richard Herrmann; John F Seymour; Chris Arthur; David Joske; Kevin Lynch; Tim Hughes
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

5.  ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Giovanni Martinelli; Gianantonio Rosti; Simona Bassi; Marilina Amabile; Angela Poerio; Barbara Giannini; Elena Trabacchi; Fausto Castagnetti; Nicoletta Testoni; Simona Luatti; Antonio de Vivo; Daniela Cilloni; Barbara Izzo; Milena Fava; Elisabetta Abruzzese; Daniele Alberti; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

6.  High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Authors:  Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung Park; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

7.  Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

Authors:  Susan Branford; Zbigniew Rudzki; Ian Parkinson; Andrew Grigg; Kerry Taylor; John F Seymour; Simon Durrant; Peter Browett; Anthony P Schwarer; Chris Arthur; John Catalano; Michael F Leahy; Robin Filshie; Kenneth Bradstock; Richard Herrmann; David Joske; Kevin Lynch; Tim Hughes
Journal:  Blood       Date:  2004-07-15       Impact factor: 22.113

8.  Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.

Authors:  V Nardi; T Raz; X Cao; C J Wu; R M Stone; J Cortes; M W N Deininger; G Church; J Zhu; G Q Daley
Journal:  Oncogene       Date:  2007-08-06       Impact factor: 9.867
  8 in total
  16 in total

1.  Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Authors:  Constance Baer; Wolfgang Kern; Sarah Koch; Niroshan Nadarajah; Sonja Schindela; Manja Meggendorfer; Claudia Haferlach; Torsten Haferlach
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

2.  Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy.

Authors:  D H Wiseman; E A Struys; D P Wilks; C I Clark; M W Dennis; E E W Jansen; G S Salomons; T C P Somervaille
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

Review 3.  Minimal residual disease in acute myelogenous leukemia.

Authors:  N M Cruz; N Mencia-Trinchant; D C Hassane; M L Guzman
Journal:  Int J Lab Hematol       Date:  2017-05       Impact factor: 2.877

Review 4.  High-dimension single-cell analysis applied to cancer.

Authors:  Lili Wang; Kenneth J Livak; Catherine J Wu
Journal:  Mol Aspects Med       Date:  2017-08-30

Review 5.  Current developments in molecular monitoring in chronic myeloid leukemia.

Authors:  Justine Ellen Marum; Susan Branford
Journal:  Ther Adv Hematol       Date:  2016-07-15

6.  Experimental generation of SNP haplotype signatures in patients with sickle cell anaemia.

Authors:  Stephan Menzel; Jian Qin; Nisha Vasavda; Swee Lay Thein; Ramesh Ramakrishnan
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

Review 7.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

8.  Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.

Authors:  Dan Jones; Suzanne Kamel-Reid; David Bahler; Henry Dong; Kojo Elenitoba-Johnson; Richard Press; Neil Quigley; Paul Rothberg; Dan Sabath; David Viswanatha; Karen Weck; James Zehnder
Journal:  J Mol Diagn       Date:  2008-12-18       Impact factor: 5.568

9.  COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations.

Authors:  Coren A Milbury; Jin Li; G Mike Makrigiorgos
Journal:  Clin Chem       Date:  2009-10-08       Impact factor: 8.327

10.  A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.

Authors:  Thomas Ernst; Franz X Gruber; Oliver Pelz-Ackermann; Jacqueline Maier; Markus Pfirrmann; Martin C Müller; Ingvild Mikkola; Kimmo Porkka; Dietger Niederwieser; Andreas Hochhaus; Thoralf Lange
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.